From 'Back' To 'Front': US FDA, Industry Experts Advise Device Manufacturers On Best Inspection 'War Room' Practices
This article was originally published in SRA
Ever since the first US Food and Drug Administration inspection took place decades ago, medtech manufacturers have relied on so-called "inspectional war rooms" - spaces where subject matter experts and others work to fulfill investigator needs. But such back rooms can cause headaches for medical device firms and stretch out inspections if they select unsuitable workers to staff and manage them.
You may also be interested in...
ConMed Corp. is company of two halves ̶ general surgery and orthopedics – and is readying itself for a renewed assault on these two markets on the back of a technology pipeline, targeted acquisitions and a new growth-winning culture, says CFO Todd Garner.
Drug pricing and access issues expose the pharmaceutical sector especially acutely to calls for companies to meet ethical and social goals, alongside commercial ones. Digital is up-ending pharma’s processes, its workplaces and its consumers. R&D productivity is spluttering. Amid this turmoil, CEOs highlight company culture – the way an organization behaves – as a crucial ingredient for success. But what is a “right” culture? Organizational culture is neither static nor singular. It is continuously influenced by acquisitions, markets, new technologies and new generations. And pharma’s history suggests that culture change cannot happen without sufficient people change.